0001213900-22-008987.txt : 20220223 0001213900-22-008987.hdr.sgml : 20220223 20220223164532 ACCESSION NUMBER: 0001213900-22-008987 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220218 FILED AS OF DATE: 20220223 DATE AS OF CHANGE: 20220223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FEBBO WILLIAM J CENTRAL INDEX KEY: 0001413987 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38543 FILM NUMBER: 22664588 MAIL ADDRESS: STREET 1: 600 CALIFORNIA ST., 9TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OptimizeRx Corp CENTRAL INDEX KEY: 0001448431 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 261265381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 WATER ST., STE. 200 CITY: ROCHESTER STATE: MI ZIP: 48307 BUSINESS PHONE: 248-651-6558 MAIL ADDRESS: STREET 1: 400 WATER ST., STE. 200 CITY: ROCHESTER STATE: MI ZIP: 48307 4 1 ownership.xml X0306 4 2022-02-18 0 0001448431 OptimizeRx Corp OPRX 0001413987 FEBBO WILLIAM J C/O OPTIMIZERX CORPORATION 400 WATER STREET, SUITE 200 ROCHESTER MI 48307 1 1 0 0 CHIEF EXECUTIVE OFFICER Common Stock 2022-02-18 4 S 0 9200 43.379 D 453138 D Common Stock 2022-02-18 4 S 0 7066 44.122 D 446072 D Common Stock 2022-02-18 4 S 0 400 44.960 D 445672 D The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.84 to $43.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.93 to $44.97. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person. /s/ William J. Febbo 2022-02-22